Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

The PKB/AKT pathway in cancer.

Carnero A.

Curr Pharm Des. 2010 Jan;16(1):34-44. Review.

PMID:
20214616
2.

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF.

Curr Cancer Drug Targets. 2008 May;8(3):187-98. Review.

PMID:
18473732
3.

PTEN, more than the AKT pathway.

Blanco-Aparicio C, Renner O, Leal JF, Carnero A.

Carcinogenesis. 2007 Jul;28(7):1379-86. Epub 2007 Mar 6. Review.

PMID:
17341655
4.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
5.
6.

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.

Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP.

Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi: 10.1126/scitranslmed.3001065.

7.

PI3K/PTEN signaling in tumorigenesis and angiogenesis.

Jiang BH, Liu LZ.

Biochim Biophys Acta. 2008 Jan;1784(1):150-8. Epub 2007 Sep 29. Review.

PMID:
17964232
8.

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.

Polivka J Jr, Janku F.

Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Epub 2013 Dec 9. Review.

PMID:
24333502
9.

Targeting the EGFR and the PKB pathway in cancer.

Klein S, Levitzki A.

Curr Opin Cell Biol. 2009 Apr;21(2):185-93. doi: 10.1016/j.ceb.2008.12.006. Epub 2009 Feb 11. Review.

PMID:
19216065
10.

PTEN and the PI3-kinase pathway in cancer.

Chalhoub N, Baker SJ.

Annu Rev Pathol. 2009;4:127-50. doi: 10.1146/annurev.pathol.4.110807.092311. Review.

11.

Novel inhibitors of the PI3K family.

Carnero A.

Expert Opin Investig Drugs. 2009 Sep;18(9):1265-77. doi: 10.1517/13543780903066798. Review.

PMID:
19589091
12.

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.

Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA.

Cancer Cell. 2009 Jul 7;16(1):21-32. doi: 10.1016/j.ccr.2009.04.012.

13.

Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.

Qazi AK, Hussain A, Hamid A, Qurishi Y, Majeed R, Ahmad M, Najar RA, Bhat JA, Singh SK, Zargar MA, Ali S, Saxena AK.

Anticancer Agents Med Chem. 2013 Dec;13(10):1552-64. Review.

PMID:
23438828
14.

Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast.

Rodríguez-Escudero I, Roelants FM, Thorner J, Nombela C, Molina M, Cid VJ.

Biochem J. 2005 Sep 1;390(Pt 2):613-23.

15.

PTEN-deficient cancers depend on PIK3CB.

Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM, Lengauer C.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13057-62. doi: 10.1073/pnas.0802655105. Epub 2008 Aug 28.

16.

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM.

J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647. Review.

PMID:
21302297
17.

Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

Xu G, Zhang W, Bertram P, Zheng XF, McLeod H.

Int J Oncol. 2004 Apr;24(4):893-900.

PMID:
15010827
18.

Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).

Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, McCubrey JA, Travali S, Libra M.

Int J Oncol. 2012 Mar;40(3):639-44. doi: 10.3892/ijo.2011.1312. Epub 2011 Dec 20. Review.

PMID:
22200790
19.

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.

Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T.

Breast Cancer Res. 2008;10(6):R101. doi: 10.1186/bcr2204. Epub 2008 Dec 3.

20.

Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.

Cassinelli G, Zuco V, Gatti L, Lanzi C, Zaffaroni N, Colombo D, Perego P.

Curr Med Chem. 2013;20(15):1923-45. Review.

PMID:
23410153

Supplemental Content

Support Center